Antigen-antibody complexes were made from allergens of the common house dust mite, Dermatophagoides pteronyssinus (Dpt) and an excess of purified autologous specific antibodies. These complexes have been used to treat Dpt-hypersensitive patients who suffered from chronic bronchial asthma. Clinical symptoms and medication intake were followed by filling in diary cards. Peak expiratory flow, measured four times a day, was also followed. Intradermal skin tests and bronchial challenge tests were performed with allergen together with an evaluation of nonspecific bronchial reactivity. Specific IgE and IgG antibodies were assayed after separation from the bulk of serum immunoglobulins by immunoadsorption. The study was carried out over two years according to a double-blind protocol.
Introduction
Ever since it was established that IgE antibodies play a central role in immediate hypersensitivity (1), suppression of its production has been a desirable therapeutic objective. Recent suppression (2) , but the practical implications of such an approach remain unclear. Suppression of allergen-specific IgE could provide advantages in this respect, but to date attempts to achieve this have been inconclusive. Chemical modification of allergens generates compounds with increased immunogenicity but little, if any, effect on IgE production (3). Tolerogens, such as allergens covalently coupled to isologous immunoglobulins (4), are effective in suppressing an IgE immune response in some, but not all animal species.
Antigen-antibody complexes could offer a valuable alternative procedure to suppress IgE antibody production. Numerous papers on the use of complexes in experimental animals have appeared (5) and been reviewed (6) . Both enhancement (7) or suppression (8) of immune response have been described. However, specific conditions under which complexes are suppressive can be defined. For example, excess of isologous IgG antibodies usually yields such complexes (9) .
The IgE immune response presents several advantages for the evaluation of the suppressive effects of antigen-antibody complexes. First, experimental work in rodents has shown that IgE production is more easily controlled than other isotypes (10) . Second, IgE-mediated diseases have long been treated in humans by regular injections of allergen, a treatment associated with increased IgG antibody production (11) . Therefore, if instead of the hoped-for suppression of specific IgE by antigen-antibody complexes, a stimulation of specific IgG antibodies occurred via increased allergen immunogenicity, then it could be argued that this could be beneficial to the patient in any case.
We recently isolated anti-allergen antibodies from the serum of patients hypersensitive to the common house dust mite Dermatophagoides pteronyssinus (Dpt)' (12). These antibodies can be used for the preparation of soluble complexes made in antibody excess after addition of allergen. We report here the results of a trial in Dpt-hypersensitive bronchial asthma patients, the specific aim of which was to determine whether inoculation of allergen-antibody complexes can result in a decrease of IgE antibody production. Due to ethical considerations, we selected a population of patients who suffered from chronic bronchial asthma exacerbated by allergen exposure and in whom conventional hyposensitization had failed. These chronically ill patients required daily medication for their asthma. Therefore, as a monitor of the efficacy of antigen-antibody complex inoculation, we decided to use any reduction in the medication (particularly corticosteroid intake) necessary for the maintenance as far as possible of a symptom-free state.
The results of the clinical trial can be summarized as follows: (a) virtual absence of side effects; (b) reduction in medication intake with no further need for oral corticotherapy; (c) early improvement of symptoms in almost every patient; (d) reduction in skin reactivity to allergen testing; (e) disappearance of specific bronchial reactivity in 50% ofthe patients with unchanged nonspecific reactivity; (f) early decrease in IgE antibody concentrations; and (g) absence of specific IgG antibody increase.
Methods
Patient selection. 39 patients (25 males and 14 females; average age 33 yr, range 16-57 yr) gave their informed consent for participation in this study. The following criteria were used for inclusion in the trial: (a) chronic bronchial asthma severe enough to require daily treatment with inhaled beta2-agonists and inhaled beclomethasone, and regular courses of oral corticosteroids (patients with systemic corticodependence were excluded, however); (b) Dpt hypersensitivity as evidenced by clinical history, skin prick test, radioallergosorbent test (4+) and specific bronchial challenge, and significant exacerbation ofasthma by allergen exposure; and (c) unsuccessful hyposensitization with Dpt, defined as regular inoculations ofallergen, in soluble or alum-adsorbed form, for at least 2 yr. The mean time interval since the last desensitization was 7.2 yr. With regard to other allergic sensitivities, eight patients were found to be sensitive to cat allergens (three in group A, three in group B, and two in group C), three were sensitive to grass pollen (one in group A and two in group C), one patient in group A was sensitive to Alternaria tenuis, and one patient in group C was sensitive to Cladosporium herbarum. The number of patients sensitive to mite allergens alone was 27 (9 in group A, 10 in group B, and 8 in group C). All patients had been followed up in our Chest Disease Unit for at least 6 mo before the beginning of the study, during which time they were instructed in basic procedures for minimizing domestic allergen exposure. The study was Table I for details of the injection schedule and amounts injected). The 13 patients in group B also received increasing amounts of 1:5 antigen-antibody complexes After the 28th treatment week, doses of complexes were kept constant and given at 14-d intervals until the end of the first year, after which they were administrated every 6 wk. Total amounts of injected material are also given for each treatment year.
given at this maintenance dose. Group C comprised 13 patients inoculated with albumin buffer alone. The maximum volume ofeach inoculate was 100 Ml given intradermally in the upper arm by the same physician (J.M.) who was unaware of the treatment regimen group to which the patients belonged. The study began in September 1985 and lasted till November 1987; the first injections were made in November 1985 and all patients were seen within the same week. During the first year oftreatment the patients were inoculated every other week and for the second year, every six weeks.
Clinical evaluation. Patients were asked to fill in a diary card evaluating diurnal and nocturnal asthma, morning breathlessness, and cough on a discontinuous intensity score from 0 to 4 (14) . Another score used for evaluation of medication intake was: 0, no medication; 1, inhaled bronchodilators (salbutamol) when required or twice daily; 2, regular bronchodilator intake, with or without theophylline; 3, inhaled beclomethasone; and 4, oral corticotherapy. Patients were instructed in the way to adapt their drug treatment according to both symptom scores and peak expiratory flow (PEF) measured before medication (minimum PEF). Inhaled beclomethasone or oral corticosteroids were added to the treatment when minimum PEF was < 80 or < 60% of expected values, respectively.
Lungfunction and bronchial challenges. Vital capacity, forced expiratory volume in 1 s (FEV 1), total lung volume, and specific airway conductance were measured at the beginning and after 1 and 2 yr of treatment using a JaegerO plethysmograph (Jaeger, Wursburg, FRG). In addition, each patient recorded his PEF with a peak-flow monitor (Vitalograph Ltd., Buckingham, UK) four times a day, before and after medication, in the morning and at night. Nonspecific and specific bronchial hyperreactivities were measured on two consecutive days after acetylcholine (Ach) or Dpt-allergen inhalation, respectively (15) .
Before evaluation of lung function, medication was discontinued for at least 12 h for beta2-agonists, 2 wk for inhaled beclomethasone, and 2 mo for oral corticosteroids. Provocation tests were not performed when the basal lung function was < 75% of normal values. l-ml solutions containing either Ach or Dpt allergens were aerosolized in a 100 X 5. 
Results
Compliance and side-effects. 36 patients completed the 2-yr study. One patient did not begin the trial and two other patients, one in group A and one in group C, were lost for follow-up for unknown reasons. Two patients were seen less regularly than scheduled during the second year of treatment but were nevertheless maintained in the study. More than 800 injections were performed without any indication of systemic side-effects. An immediate skin reactivity to inoculation together with minor local pruritus was observed in 10 of the 26 patients treated. The wheal size was moderate (0.5-2 cm2) in all but two patients where it attained a maximum of 10.8 cm2. These skin reactions occurred only at the early stages of the injection regimen, and after the second month of treatment these patients could not be distinguished from the others on this basis. The patients who presented an initial skin reactivity were those for whom the calculated allergen-antibody ratio was < 1:5, indicating that free allergen was present in the solution used for inoculation. Inoculation of the carrier buffer produced an erythema and pruritus in two placebo patients. At the end of the study, patient group allocation (treated vs. placebo) was correctly guessed by the physician (J.M.). Each of the treated patients recognized the benefit of the therapy, whereas one-third of placebo patients thought they were given active treatment. Medication scores. Drug intake was monitored on diary cards using a discontinuous scale. To facilitate analysis, patients were allowed access to only a limited number of drugs, namely salbutamol and beclomethasone in pressurized aerosols, and methylprednisolone in tablets. No significant difference in medication intake was observed between groups in the prestudy monitoring ofthe patients. Fig. 2 shows the evolution of medication intake over the first year of treatment. For the sake of clarity, the mean drug intake over the six weeks before the trial was arbitrarily designated as 100. The first significant reduction in medication was seen round about the 18th week and continued to improve thereafter in both groups A and B (Wilcoxon matched pair test, P < 0.001), while drug intake actually increased in group C. This reduction was well illus-\11 \ Figure 2 . Evolution of medication intake in group A (u), PEF and lung function. PEF were measured four times a day, before and after drug inhalation. Values for both minimum and maximum PEF were averaged over 2 wk. Fig. 3 shows the evolution over 2 yr of treatment. This indicates that despite careful patient randomization group A patients had significantly lower values for both minimum and maximum PEF than either of the other groups (Mann-Whitney U test, P < 0.05). Nevertheless, their values increased steadily until reaching levels similar to the two other groups after 30 liters/kPa-s-' at the beginning of the study for groups A, B, and C, respectively; 1.27, 1.07, and 1.22 after 1 yr; and 0.96, 1.4, and 1.07 at the end of the trial. FEV 1 values were significantly lower (Mann-Whitney U test, P < 0.05) in group A patients than in group C patients at the beginning ofthe study.
Skin tests. Intradermal skin tests were performed on three occasions, at the beginning of the trial and after 1 and 2 yr of treatment. Nonspecific skin reactivity was evaluated by the inoculation of histamine at a concentration of I mg/ml. Fig. 4 shows the skin wheal area obtained after intradermal inoculation of allergen at different dosages before the study and 1 and 2 yr afterward. Reactivity to 1 mg/ml histamine was unchanged over the study period (data not shown). A progressive decrease in the wheal area elicited by inoculation of allergen was observed in both groups A and B over the entire concentration range (Wilcoxon matched pair test, P < 0.001 for both groups at 400 ng allergens/ml). No significant change was detected in the allergen skin reactivity of the placebo group.
Bronchial challenges. Challenges were carried out three times on each patient at exactly 1-yr intervals to avoid the effect of seasonal variations on bronchial hyperreactivity. Only patients able to do without bronchodilators for 12 h without steroid treatment, and whose basal lung function was at least 75% of the normal values were challenged. At the beginning and after 1 yr of treatment the number of patients who qualified for such challenges was 5 of 11 in group A, 6 of 13 in group B, and 8 of 12 in group C (Fig. 5) . After the second year three additional treated patients, one in group A and two in group B, could be challenged with Ach. One patient in group A did not come back in time for his second year challenge. Nonspecific bronchial reactivity to Ach was unchanged after 1 or 2 yr of treatment for both treated groups (Wilcoxon matched pair test, P = NS). In contrast, a significant increase in reactivity was observed in group C patients (Wilcoxon matched pair test, P < 0.05).
Allergen provocation tests were carried out 24 h after Ach provocation, ensuring first that the basal lung function was 2 75% of normal values. Fig. 6 shows the bronchial allergen sensitivity before the study and after 1 Fig. 9 shows the change in individual specific IgG values between the beginning and end of the study. Each data point is the mean of three estimates made on consecutive serum samples. Six patients in group A showed a significant decrease of specific IgG (Wilcoxon matched pair test, P < 0.02), three had unchanged concentrations, and three had increased concentrations. The overall evolution of specific IgG was not significant in group A. Within patients of group B, 10 patients showed a significant reduction in IgG concentrations, 1 showed unchanged con- Nov '87 centrations, and 2 had increased concentrations. Group B as a whole had significantly lower IgG concentrations at the end of the trial than initial values (Wilcoxon matched pair test, P < 0.05). In the placebo group, four patients showed an increased IgG concentration, three had unchanged values, and four had a lower concentration, but these changes were not significant. Interestingly, reduction of IgG concentrations of placebo patients occurred later during the study than changes induced by the treatment. A positive correlation was found between the changes in serum IgE and IgG antibodies (r = 0.86, P < 0.01) (Fig. 10) . Correlation of specific antibody concentrations with other clinical parameters. Finally, we examined the possible relationships of specific antibody concentrations with other parameters. No significant correlation was found between IgE or IgG specific antibody levels and symptoms, drug intake, PEF, skin tests, or specific and nonspecific bronchial challenges.
Discussion
Inoculation of allergen-antibody complexes results in a fast and significant improvement of bronchial asthma in patients hypersensitive to Dpt. Compared with conventional hyposensitization, this treatment requires 100-fold less allergen, is probably safer, and relies on a different mechanism of action.
We chose to study the human immune response to Dpt as hypersensitivity to this mite is the most common cause of allergic bronchial asthma in our country (16) . Moreover, the main Dpt allergens have been characterized and are available commercially (17) . In previous work (Saint-Remy, J. M., and M. G. Jacquemin, unpublished observations) we have demonstrated that mixing allergen with specific antibody in a 1:5 (wt/wt) ratio enabled us to construct complexes in sufficient antibody excess to neutralize the wheal and flare skin reaction elicited by inoculating free allergen in a majority of atopic patients. Although we observed variations from one patient to another in the precise ratio of antigen over antibody necessary to achieve this allergen neutralization effect, it was felt that a 1:5 ratio was an acceptable standard ratio.
As this is the first trial of antigen-antibody complexes in man as far as we are aware, we felt bound, for obvious ethical reasons, to first study patients whose clinical status had not improved by either pharmacologic or immunologic treatment. Hence, patients included in this trial were suffering from multifactorial chronic bronchial asthma which necessitated continuing medication, and in whom conventional immunotherapy had not succeeded. Although we understood that such selection criteria could introduce a study bias, we considered that the biggest drawback would be to mask the effects of treatment with antigen-antibody complexes and thus, if anything, underestimate its impact. The study was therefore designed to answer two questions. First, would the treatment lead to a reduction in the medication needed by these patients to stay as symptom-free as possible? To optimize patient compliance and continued participation in the trial, we favored this aspect of the study design rather than trying to impose a general reduction in medication intake. Second, would the treatment induce alterations in parameters of immediate hypersensitivity, e.g., skin tests and specific bronchial provocation tests or serum concentration of specific antibodies?
With regard to the double-blind design of this study, the immediate skin reactivity resulting from inoculation in some treated patients might have introduced a bias. Addition of histamine to the placebo solution was not considered as it would have permitted identification of the placebo group as soon as the skin reactivity of treated patients had disappeared. As only a proportion oftreated patients had an immediate skin reactivity, the latter being present only during the first weeks of the trial, and as some of the placebo patients experienced local pruritus and erythema, it is unlikely that the clinician was able to guess patient group allocation. In addition, the clinical evaluation was based on the patients' own records and the decision to adjust drug treatment on daily measurements of PEF. Both clinical and biological data were analyzed blindly by one of us variations. However, because of this constraint the number of patients who could be challenged was reduced, since either basal lung function was not satisfactory after discontinuation of drug or the patients were unable to withhold medication long enough to comply with the protocol. Treated patients who were challenged after one or two years had a parallel clinical and biological evolution to those who were not tested. This might suggest that bronchial specific reactivity was reduced in every treated patient. It might also be that reduction or loss in bronchial reactivity to the allergen occurred earlier during the study; bronchial reactivity has indeed been correlated to serum-specific IgE antibodies (22) . In contrast to the marked reduction in allergen sensitivity, nonspecific bronchial reactivity was not reduced or was only marginally reduced at the end of the second year of treatment. The question whether this nonspecific hyperreactivity could also be diminished over a longer term remains open, although additional observations (Machiels, J. J., P. M. Lebrun, M. G. Jacquemin, and J. M. R. Saint-Remy, manuscript in preparation) would suggest that it could well be the case in some patients.
Late bronchial reactivity is considered a more relevant parameter than immediate reactivity to follow up hyposensitization efficacy (23) , but can only be performed in patients requiring no treatment when they are not exposed to allergen. In this study late reactivity could not be evaluated since the medication had to be resumed shortly after the challenge. Nevertheless, none of the treated patients who were able to discontinue their symptomatic treatment experienced a fall in PEF on the day after bronchial challenge, regardless of the presence or absence of an immediate reaction to challenge. In contrast, placebo patients exhibited a significant drop in PEF requiring temporary increase in medication on the day after challenge.
There are at least three reasons why this treatment is likely to be safer than usual hyposensitization. First, considerably less allergen is used for the treatment. For instance, the total amount of Dpt inoculated during a standard hyposensitization treatment would be 350 Mig, with an average of 20 injections to reach the maintenance dosage. In this study, the amounts of allergen for the same number of injections was 3.2 ,g in group A and 1 Mg in group 13. Second, antibodies present in the complexes inhibit efficiently the binding of specific IgE antibodies to Dpt allergens in vivo (12). We have, however, shown that anti-Dpt IgG do not bind to the same epitopes of Dpt allergens as do specific IgE (24). It is therefore likely that inhibition occurs by steric hindrance. Third, the intradermal route instead of the usual subcutaneous one limits the allergen diffusion rate after inoculation. The excellent tolerance to treatment and the absence of any systemic side-effects bear out these observations. Our observations made on specific antibodies diverge from findings associated with conventional hyposensitization for several reasons. First, we did not see an early increase in IgE concentrations, which is generally induced by hyposensitization. Second, a major reduction in IgE concentrations occurred early, reaching significance after only 10 wk of treatment. Third, specific IgG concentrations were not raised as a result of treatment. This obviously questions the importance of specific IgG antibodies in the immunologic treatment for immediate hypersensitivity to airborne allergens. In hyposensitization trials an inverse relationship can sometimes be found between specific IgG and IgE antibodies (25) . In the These findings also argue for a different mechanism of action for these two treatments.
The methods used to assay serum-specific IgE or IgG antibodies in this study differ from those used in other studies but were used to allow both a careful follow-up of IgG antibodies and an evaluation of other parameters like anti-idiotypic and anti-isotypic antibodies (24). Anti-allergen IgG antibodies are difficult to assay in serum since they represent a very small percentage of the total IgG. Existing methods (26) have been found difficult to use by other investigators. Our methodology has been critically reviewed and found suitable for this application (12). Samples were applied to the column in a random order and were checked for completeness of adsorption. Conditions used for elution of bound antibodies from the column were optimized using radiolabeled specific antibodies. Moreover, in another study using similar allergen-antibody complexes,2 serum IgG antibodies were titrated by an independent laboratory (Prof. F. Atkinson, Johns Hopkins University, Baltimore, MD) and found to remain below the lower level of sensitivity throughout the trial. In the same study we also evaluated our technique of IgE antibody titration by comparing it with two other assays for serum IgE, the radioallergosorbent test and a latex agglutination test developed in our laboratory (27) .
The mechanism by which allergen-antibody complexes operate is at present unknown. Such complexes are potent inducers of anti-idiotypic antibodies (28) , which are capable of suppressing in vitro IgE production (29). We and others (30, 31) have demonstrated the presence of spontaneously produced anti-idiotypic antibodies specific to anti-allergen antibodies. More work is required to understand the mechanism of action, but we are convinced of both the clinical and experimental interests of this treatment.
Finally, we have considered that the clinical effect resulting from inoculation of allergen-antibody complexes might be attributable either to low doses ofallergen or to specific antibodies. This question has been examined in two other clinical studies. First, bronchial asthma related to grass pollen exposure was not prevented by injections of allergen alone, whereas inoculation of allergen-antibody complexes was efficient (Machiels, J. J., P. M. Lebrun, M. A. Somville, M. G. Jacquemin, and J. M. R. Saint-Remy, manuscript in preparation). Second, in another study on Dpt hypersensitivity (Machiels, J. J., M. A. Somville, S. J. Lebecque, M. G. Jacquemin, and J. M. R. Saint-Remy, manuscript in preparation), comparison of patients treated with specific antibodies alone with a group inoculated with allergen-antibody complexes showed no benefit from antibody inoculation.
